47 related articles for article (PubMed ID: 2984649)
1. ATR-101, a selective ACAT1 inhibitor, decreases ACTH-stimulated cortisol concentrations in dogs with naturally occurring Cushing's syndrome.
Langlois DK; Fritz MC; Schall WD; Bari Olivier N; Smedley RC; Pearson PG; Bailie MB; Hunt SW
BMC Endocr Disord; 2018 May; 18(1):24. PubMed ID: 29720169
[TBL] [Abstract][Full Text] [Related]
2. Role of "old" pharmacological agents in the treatment of Cushing's syndrome.
Ambrogio AG; Cavagnini F
J Endocrinol Invest; 2016 Sep; 39(9):957-65. PubMed ID: 27086313
[TBL] [Abstract][Full Text] [Related]
3. Dopamine D2 receptor gene expression in human adenohypophysial adenomas.
Stefaneanu L; Kovacs K; Horvath E; Buchfelder M; Fahlbusch R; Lancranjan L
Endocrine; 2001 Apr; 14(3):329-36. PubMed ID: 11444429
[TBL] [Abstract][Full Text] [Related]
4. Evaluation and treatment of Cushing's syndrome.
Nieman LK; Ilias I
Am J Med; 2005 Dec; 118(12):1340-6. PubMed ID: 16378774
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Cushing's disease in children.
Bergstrand CG; Nilsson KO
Acta Paediatr Scand; 1982 Jan; 71(1):1-6. PubMed ID: 6291313
[No Abstract] [Full Text] [Related]
6. Six year remission of ACTH-dependent Cushing's syndrome using bromocriptine.
Atkinson AB; Kennedy AL; Sheridan B
Postgrad Med J; 1985 Mar; 61(713):239-42. PubMed ID: 2984649
[TBL] [Abstract][Full Text] [Related]
7. ACTH and cortisol response to bromocriptine, and results of long-term therapy, in Cushing's disease.
Kennedy AL; Sheridan B; Montgomery DA
Acta Endocrinol (Copenh); 1978 Nov; 89(3):461-8. PubMed ID: 212917
[TBL] [Abstract][Full Text] [Related]
8. Cortisol-suppressible dexamethasone-nonsuppressible cyclic Cushing's disease with evidence of clinical and biochemical remission with bromocriptine.
Mercado-Asis LB; Murayama M; Yamakita N; Morita H; Mune T; Yasuda K; Miura K
Endocrinol Jpn; 1991 Jun; 38(3):315-24. PubMed ID: 1665413
[TBL] [Abstract][Full Text] [Related]
9. Cyclic Cushing's disease in long-term remission with a daily low dose of bromocriptine.
Adachi M; Takayanagi R; Yanase T; Sakai Y; Ikuyama S; Nakagaki H; Osamura Y; Sanno N; Nawata H
Intern Med; 1996 Mar; 35(3):207-11. PubMed ID: 8785455
[TBL] [Abstract][Full Text] [Related]
10. Reduction of pituitary tumor size with clinical and biochemical improvement with bromocriptine in a normoprolactinemic Cushing's disease.
Hayashi H; Mercado-Asis LB; Murayama M; Yamakita N; Yasuda K; Miura K
Endocrinol Jpn; 1990 Dec; 37(6):875-82. PubMed ID: 1966282
[TBL] [Abstract][Full Text] [Related]
11. A case of Cushing's disease successfully treated with bromocriptine.
Sumiya N; Hiramatsu K; Arimori S
Jpn J Med; 1990; 29(2):185-90. PubMed ID: 2172607
[TBL] [Abstract][Full Text] [Related]
12. A survey of results with transsphenoidal surgery in Cushing's disease.
Burch W
N Engl J Med; 1983 Jan; 308(2):103-4. PubMed ID: 6847933
[No Abstract] [Full Text] [Related]
13. Adrenocorticotropin and cortisol responsiveness to thyrotropin-releasing hormone and luteinizing hormone-releasing hormone discloses two subsets of patients with Cushing's disease.
Pieters GF; Smals AG; Goverde HJ; Pesman GJ; Meyer E; Kloppenborg PW
J Clin Endocrinol Metab; 1982 Dec; 55(6):1188-97. PubMed ID: 6290524
[TBL] [Abstract][Full Text] [Related]
14. Long term bromocriptine therapy in Cushing's disease.
Kapcala LP; Jackson IM
J Endocrinol Invest; 1982; 5(2):117-20. PubMed ID: 6284830
[TBL] [Abstract][Full Text] [Related]
15. Adrenocorticotropin-secreting pituitary adenomas originate from the anterior or the intermediate lobe in Cushing's disease: differences in the regulation of hormone secretion.
Lamberts SW; de Lange SA; Stefanko SZ
J Clin Endocrinol Metab; 1982 Feb; 54(2):286-91. PubMed ID: 6274899
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
